EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

HER2-targeted therapy has yielded a significant clinical benefit in patients with HER2+ breast cancer, yet disease relapse due to intrinsic or acquired resistance remains a significant challenge in the clinic. Here, we show that the protein phosphatase 2A (PP2A) regulatory subunit PPP2R2B is a cruci...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Yi, Oguz, Gokce, Lee, Wee Chyan, Lee, Puay Leng, Ghosh, Kakaly, Li, Jiayao, Wang, Panpan, Lobie, Peter E., Ehmsen, Sidse, Ditzel, Henrik J., Wong, Andrea, Tan, Ern Yu, Lee, Soo Chin, Yu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674491/
https://www.ncbi.nlm.nih.gov/pubmed/33208750
http://dx.doi.org/10.1038/s41467-020-19704-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674491/
https://www.ncbi.nlm.nih.gov/pubmed/33208750
http://dx.doi.org/10.1038/s41467-020-19704-x

Ejemplares similares